Healthcare Industry News: Beckman Coulter
News Release - April 10, 2006
Exagen Diagnostics Names Thomas O'Connor Vice President, SalesALBUQUERQUE, N.M., April 10 (HSMN NewsFeed) -- Exagen Diagnostics, Inc., which develops and commercializes genomic marker-based in vitro diagnostic (IVD) kits for predicting risk of recurrence or treatment response, today announced that Thomas O'Connor has joined the company as vice president, sales. Based in Exagen's Austin, Texas, office, O'Connor oversees all sales and managed care personnel and will have worldwide responsibility as Exagen expands its sales force in the coming year.
"Thomas has an outstanding record of sales success in the clinical diagnostics arena, and we welcome his expertise as Exagen prepares to launch its breast cancer products within the next year," said Exagen CEO James McClintic.
O'Connor has 20 years of sales, sales team leadership, management and business development experience, during which he consistently exceeded targets and grew business and market share several times the industry average. Prior to joining Exagen, O'Connor held positions as business development manager and North America sales manager for Beckman Coulter, Inc., which manufactures clinical diagnostics and biomedical testing instrument systems, tests and supplies. He also served as director of sales and marketing at Quantachrome Instrument Corp. and has held sales positions at Varian Instruments, Leeman Labs, Inc., Coulter Corp. and Micromeritics Instrument Corp. O'Connor holds a B.S. in chemistry/biology from State University of New York.
About Exagen Diagnostics, Inc.
An emerging leader in the development of predictive in vitro diagnostic (IVD) kits, Exagen is uniquely able to discover, validate and productize small sets of genomic markers for use in oncology, infectious disease and other indications. The company's first tests predict the risk of breast cancer recurrence, so that women with a low or elevated risk of recurrence can be identified with high accuracy. Exagen plans to submit its first test to the Food and Drug Administration for clearance later this year, and will be the first to market a set of genomic markers to predict breast cancer recurrence using a fluorescent in situ hybridization (FISH) kit. For more information, visit http://www.exagen.com.
Source: Exagen Diagnostics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.